Trial Profile
Safety of pembrolizumab in patients who stopped ipilimumab due to immune-related adverse events
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.